The effect of beta-receptor stimulation on the activity of the inhibitor of cAMP-dependent protein kinase.
Isoprenaline and adrenaline produced an increase of cAMP content and a decrease of the activity of the endogenous inhibitor of cAMP-dependent protein kinase (type I inhibitor) in human lymphocytes and in rat heart. The maximal effect was seen at a concentration of 10(-6) M. Noradrenaline and dopamine required much higher concentration to elicite the same effect. The decrease of type I inhibitor activity was mediated through beta-adrenergic receptors because propranolol, but not phentolamine, blocked the effects produced by isoprenaline. Stimulation of beta-adrenergic receptors did not influence the activity of type II inhibitor.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism*; D004983:Ethanolamines / Q000494:pharmacology; D047908:Intracellular Signaling Peptides and Proteins; D007545:Isoproterenol / Q000494:pharmacology; D008214:Lymphocytes / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D011943:Receptors, Adrenergic, beta / Q000502:physiology
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D002352:Carrier Proteins; D004983:Ethanolamines; D047908:Intracellular Signaling Peptides and Proteins; D011943:Receptors, Adrenergic, beta; C015482:protein kinase modulator; D011433:Propranolol; D000242:Cyclic AMP; D007545:Isoproterenol; D010646:Phentolamine